Results 91 to 100 of about 3,353 (184)

Role of transporters in the disposition of a novel β-lactamase inhibitor: relebactam (MK-7655)

Journal of Antimicrobial Chemotherapy, 2019
To identify the transporters involved in renal elimination of relebactam, and to assess the potential of relebactam as a perpetrator or victim of drug-drug interactions (DDIs) for major drug transporters.A series of bidirectional transport, uptake and inhibition studies were conducted in vitro using transfected cell lines and membrane vesicles.
Grace, Chan, Robert, Houle, Meihong, Lin, Jocelyn, Yabut, Kathleen, Cox, Jin, Wu, Xiaoyan, Chu   +6 more
openaire   +2 more sources

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility

Iranian Journal of Microbiology, 2021
Background and Objectives: Imipenem/relebactam (IMP/R) is a newly FDA approved β-lactam/β-lactamase inhibitor combination. Relebactam ability to restore IMP activity could differ according to the cause of imipenem non-susceptibility.
Mervat El-Sayed Mashaly, Ghada El-Saeed Mashaly   +1 more
doaj  

New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections

Antibiotics
Nosocomial central nervous system (CNS) infections with carbapenem- and colistin-resistant Gram-negative and vancomycin-resistant Gram-positive bacteria are an increasing therapeutic challenge. Here, we review pharmacokinetic and pharmacodynamic data and
Roland Nau, Jana Seele, Helmut Eiffert
doaj   +1 more source

Table_1_Rapid Detection of KPC-Producing Enterobacterales Susceptible to Imipenem/Relebactam by Using the MALDI-TOF MS MBT STAR-Carba IVD Assay.DOCX

, 2020
KPC-producing Enterobacterales represent a serious public health concern. Limited therapeutic options are available for treatment, however, the novel combination of imipenem/relebactam represents a promising alternative.
Germán Bou (309522), Marina Oviaño (8503590), Eva Gato (8503593)   +2 more
core   +1 more source

Actividad de una nueva combinación de β-lactámico e inhibidor de β-lactamasas (imipenem/relebactam)

, 2019
[spa] Pseudomonas aeruginosa es uno de los patógenos oportunistas con mayor capacidad de desarrollar resistencia a antibióticos, ya sea por mutaciones cromosómicas o por la adquisición de genes de resistencia; lo que conlleva a la necesidad de ...
Orellana Ponce, Rocío Antonela
core  

Adverse Event Signals Associated with Beta-Lactamase Inhibitors: Disproportionality Analysis of USFDA Adverse Event Reporting System

Journal of Xenobiotics
Background: Beta-lactamase inhibitors (BLIs) are widely used with beta-lactam antibiotics to combat resistant infections, yet their safety profiles, especially for newer agents, remain underexplored.
Kannan Sridharan, Gowri Sivaramakrishnan
doaj   +1 more source

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)

, 2017
Relebactam (formerly MK-7655) is an inhibitor of class A and C β-lactamases, including Klebsiella pneumoniae carbapenemase (KPC), and is currently in clinical development in combination with imipenem-cilastatin. Using Clinical and
Sibylle H. Lob, Krystyna M. Kazmierczak, Daniel F. Sahm, Katherine Young, Mary R. Motyl, Meredith A. Hackel, James A. Karlowsky   +6 more
core   +1 more source

In Vitro Efficacy of Imipenem/Relebactam Against Imipenem Resistant Gram-Negative Strains Isolated from a Tertiary Care Hospital

Pakistan Armed Forces Medical Journal
Objective: To determine in vitro efficacy of Imipenem/Relebactam against multi-drug resistant strains. Study Design: Cross-sectional study. Place and Duration of Study: Department of Microbiology, Fauji Foundation Hospital (FFH) Rawalpindi, Pakistan
Saima Ishtiaq, Sonia Tahir, Muhammad Waqas Abbas, Haider Ali, Saima Syed, Fatima Kareem   +5 more
doaj   +1 more source

Emergence of co-resistance to imipenem/relebactam and ceftazidime/avibactam in clinical Klebsiella pneumoniae ST11 clone due to KPC-2 N132S and CTX-M-65 S130G/P167S substitutions

Antimicrobial Agents and Chemotherapy
Two episodes of imipenem/relebactam and ceftazidime/avibactam co-resistant Klebsiella pneumoniae infections were identified in a Chinese hospital with an 8-month interval.
Yiqi Fu, Yuchao Zhang, Jun Zhao, Jiahong Xie, Haishen Kong, Tingting Yang, Wei Chen, Min Xu   +7 more
doaj   +1 more source

In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program

, 2018
Relebactam is a non-β-lactam, bicyclic diazabicyclooctane β-lactamase inhibitor of class A and class C β-lactamases, including Klebsiella pneumoniae carbapenemases (KPCs).
Sibylle H. Lob, Krystyna M. Kazmierczak, Daniel F. Sahm, Katherine Young, Mary R. Motyl, James A. Karlowsky   +5 more
core   +1 more source